OMDA · Omada Health, Inc.

The thesis

Omada Health is still growing revenue and members far faster than its share price has risen, and the shares closed at $19.01 on 27 October 2026, one cent above the $19 June 2025 IPO price. The third-quarter 2026 report, due after the market close on 5 November 2026, settles whether second-half revenue supports the $334-340 million full-year guide. Until then the evidence points to the shares trailing the S&P 500 rather than beating it.

The narrative is maturing: the GLP-1 (weight-loss drug) companion-care story is well known, and analyst target actions on 11 September 2026 did not hold the price. The only company items since the 15 October 2026 note are research-presentation announcements on 20 October 2026 and 21 October 2026 about the GLP-1 care track, and a 23 October 2026 PRISM MarketView item on National Physical Therapy Month. No SEC filings appeared in the period.

Bullish and bearish views on Omada Health, Inc.

The bull case on Omada Health, Inc. (OMDA), in brief: Growth and profit both improved. The bear case: Revenue per member is barely rising.

Bull case

• Growth and profit both improved. Omada's 6 August 2026 release reported second-quarter revenue of $88 million, up 43% year over year. Gross margin rose to 73% from 66%, net income was $5 million, and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) was $11 million.
• Membership is still expanding fast. Total members rose 45% year over year at 30 June 2026, per the same release.
• Guidance leaves upside out. The full-year 2026 guide is $334-340 million of revenue and $21-27 million of adjusted EBITDA. The company says it excludes material contribution from GLP-1 prescribing, Flex Care and the cholesterol program.
• Clinical evidence is being published. On 20 October 2026 Omada announced it will present published research showing members of its GLP-1 care track lost more weight and improved body composition more. On 21 October 2026 it announced a peer-reviewed presentation at the World Obesity and Weight Management Congress.
• Analyst targets sit far above the price. Barclays raised its target to $27 on 11 September 2026, Needham kept $28 and BTIG kept $35, per Benzinga. The consensus target was $26.67 on 1 October 2026, per MarketBeat; no October target changes turned up in searches.

Bear case

• Revenue per member is barely rising. Trailing twelve-month revenue per total member was $284 at 30 June 2026, up about 2% year over year. Growth depends almost entirely on adding members.
• The guide implies slower growth. The guide midpoint equals 30% full-year growth, below the 43% second-quarter rate. A drift toward the 20% long-term floor set at the 10 September 2026 Investor Day would test the valuation.
• Positive coverage did not hold the price. After the 11 September 2026 target actions, the adjusted close was $20.43 on 18 September 2026, $20.41 on 1 October 2026, $18.22 on 14 October 2026 and $19.01 on 27 October 2026. The shares sit 29.0% below the $26.78 52-week high.
• The product ramp has no dates. The Investor Day targets carry no attainment year and no dated revenue schedule for GLP-1 prescribing, Flex Care or the cholesterol program.
• Leadership changes during the 2027 selling season. President Wei-Li Shao becomes chief executive on 1 January 2027, and co-founder Sean Duffy becomes Founder and Executive Chair, per the 6 August 2026 release.

Price setup

The adjusted daily close was $19.01 on 27 October 2026, against $18.22 on 14 October 2026. That is level with the $19 IPO price and 29.0% below the $26.78 52-week high. The 14-day relative strength index (RSI) is 40.1, weaker than neutral but not oversold. The shares are down 3.5% over three months.

The $22 area, which the shares failed to reclaim in September, remains well overhead. The $19 IPO price is being tested from both sides rather than cleanly held or lost. The next reference below is $16, a round level well under the IPO price.

Crowding evidence is thin. There is no gap above a rising moving average, and the latest company items are routine announcements. The one visible pressure is scheduled insider selling under Rule 10b5-1 plans, including President Wei-Li Shao's plan adopted 13 March 2026. The earnings date, 5 November 2026, is the nearest source of a sharp move in either direction.

Catalysts, next 30 days

• 1 January 2027 (outside the 30 days): Chief executive handover to Wei-Li Shao. The third-quarter call is the next read on continuity and on 2027 employer demand.

Elapsed catalysts

• The company announced the date on 13 October 2026, as reproduced by aggregator sites. The report shows whether revenue growth stays near the 43% second-quarter rate, whether member growth holds near 45%, and whether revenue per member moves off $284. (passed 24d ago)

What would change the view

The case for lagging the index breaks if the third-quarter report shows revenue growth holding well above the 30% the guide implies, with revenue per member rising clearly from $284 and the full-year guide raised toward the top of or above $340 million. A raised guide that includes GLP-1 prescribing revenue would be a stronger signal still.

The case also changes if the shares close firmly above the $22 area, which would show the September selling has been absorbed. On the downside, a cut to the $334-340 million revenue guide, or member growth falling sharply from 45%, would confirm the weaker read. A daily close below $16 would put the shares well under the IPO price and end the thesis as written.

What it trades with

Omada trades as a recently listed, growth-oriented digital health company. Its price has followed company-specific events, such as results and analyst target changes, more than any sector move in recent weeks. Employer health-benefit budgets and GLP-1 drug pricing and coverage news are the outside factors most tied to its product. The sample of public trading since the June 2025 IPO is short, so any relationship to broader indexes is not stable enough to quantify here.